Skip to main content

Table 2 Comparison of phase III clinical trials and post marketing data on PCV efficacy

From: Vaccination ecosystem health check: achieving impact today and sustainability for tomorrow

Outcome

Phase III Clinical Trial

Post introduction

IPD

93.9% (95% CI: 79.6–98.5) [13]

>99% [14]

Otitis media

7.0% (95% CI: 4.1–9.7) [13]

20% (95% CI: 4–34) [15]

All cause pneumonia (<5Y)

6% (95% CI:-1.5–11) [16]

39% (95% CI: 22–52) [17]

Cost-effectiveness

US$80,000/QALY [18]

US$75,000/QALY [19]

  1. IPD Invasive pneumococcal diseases, CI Confidence interval, QALY Quality-adjusted life year
Back to article page

BMC Proceedings

ISSN: 1753-6561

Contact us